ALK and lung carcinoma: Consistent with the data in the lung cancer patient cell lines, both filanesib and BRD9876 significantly reduced the length of BEAS-2B:EML4–ALK V3 cells but had no effect on the length of BEAS-2B:EML4–ALK V1 cells (Fig. 2, D–F).